Tag Archives: AstraZeneca

Merger Mania: When the Music Stops

As expected, the PFE/AZ saga has just begun to play out, and as we listen to the music of mega-mergers once again, I suspect that we will shortly be entering a transition where the tone will become a bit more hostile. Pfizer has been down this road before, when the deal to buy Warner Lambert in 2000 for $90 billion turned somewhat hostile. At […]
Posted in Deals, Guest Blog, Op-Ed | Also tagged , , | 1 Comment

Pfizer–AstraZeneca: Implications for the Future of International Pharma

By Peter O’ Donnell. The Pfizer-AstraZeneca courtship raises many fascinating questions about the future shape of the international pharmaceutical industry, but it is also revealing some remarkable displays of parochialism. Even the olympian Financial Times has been displaying some nationalistic sympathies that sit oddly with its customary laissez-faire liberalism. A recent editorial seemed to argue strongly for some form […]
Posted in Deals, Europe, Global, Guest Blog, Op-Ed, Safety | Also tagged , | 2 Comments

The United Kingdom: Rx for America's Pharma Tax Blues?

by Tom Norton The dizzying flurry of press releases from both Pfizer Inc. and AstraZeneca over a possible PFE acquisition of AZN have Rx experts on both sides of the Atlantic buzzing… From the US side, the most frequent thing that I have heard over the last 48 hours is, “You have got to be […]
Posted in Corporate Responsibility, Deals, Europe, FDA, Global, Guest Blog, leadership, Legal, People, Strategy | Also tagged , , , , , , , | 1 Comment

Pfizer’s AZ Bid Draws Mixed UK Reaction

The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK. Linda McCulloch of Britain’s biggest union, Unite, said the bid is “very worrying for the UK workforce”, adding that it is “absolutely crucial” that there should be “guarantees of no jobs losses and for the protection on the UK’s […]
Posted in Deals, Europe, Global, Supply Chain | Also tagged , , | Leave a comment

Big Pharma’s Big Tuesday: A New Age of Megamerger?

What’s the opposite of Black Tuesday? White Tuesday? Bright Tuesday? Because Tuesday the stock market was buzzing following the news that Novartis is to acquire GSK’s cancer drugs business, while selling its vaccines division to GSK. With the speculation of a $100bn Pfizer bid for AstraZeneca and Valeant Pharmaceuticals added in, prices went soaring. As of […]
Posted in Deals, Europe, Global, Strategy | Also tagged , , , , | Leave a comment
  • Categories

  • Meta